This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mellin, H.-E. Articles by Madsen, P. O. Search for Related Content PubMed PubMed Citation Articles by Mellin, H.-E. Articles by Madsen, P. O.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1977 February; 11(2): 262-266
Copyright © 1977 American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Cefamandole in Patients with Normal and Impaired Renal Function

^* Urology Section, Veterans Administration Hospital, Madison, Wisconsin 53705
Department of Surgery, School of Medicine and School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53706

ABSTRACT

The pharmacokinetics of cefamandole, a new cephalosporin, were investigated in 23 patients with urinary tract infections and normal or varying degrees of impairment of renal function. A daily dose of 1.5 to 3.0 g administered intramuscularly was tolerated well and resulted in very high urine concentrations. The pharmacokinetics of the antibiotic were compared with isotopically labeled [¹³¹I]hippurate and [¹²⁵I]iothalamate, which were used for determination of effective renal plasma flow and glomerular filtration rate, respectively. It was shown that cefamandole was excreted by glomerular filtration as well as by active tubular secretion. Probenecid inhibited the tubular secretion of cefamandole. The serum half-life of cefamandole in patients with normal renal function was approximately 1.5 h and increased in patients along with increasing impairment of renal function. Our studies indicate that a dosage regimen of 1 g of cefamandole every 8 h in patients with normal renal function results in urine concentrations sufficiently high for treatment of most common urinary tract infections. In patients with impaired renal function, the dosage interval should be increased or the dosage lowered according to the serum creatinine values.

This article has been cited by other articles:

• Berkhout, J., Visser, L. G., van den Broek, P. J., van de Klundert, J. A. M., Mattie, H. (2003). Clinical Pharmacokinetics of Cefamandole and Ceftazidime Administered by Continuous Intravenous Infusion. Antimicrob. Agents Chemother. 47: 1862-1866 [Abstract] [Full Text]